Edit profile Logout

A NURSE’S GUIDE TO BLINCYTO® ADMINISTRATION

A video developed in collaboration with Acute Leukaemia
Clinical Nurse Vanessa Donati

Watch

The full video features:

  • An introduction to BLINCYTO® and its mechanism of action [00:26]
  • Details around the types of patients who may benefit from treatment with BLINCYTO® [01:18]
  • A guide to BLINCYTO® dosing and administration [05:07]
  • An infusion checklist for BLINCYTO® [15:23]
  • Important information on recognising adverse events [19:28]

FREQUENTLY ASKED QUESTIONS FOR BLINCYTO® ADMINISTRATION

This FAQ video and corresponding document, developed in collaboration Acute Leukaemia Clinical Nurse Vanessa Donati, illustrate how Austin Health staff manage patients on BLINCYTO®, and includes additional practical advice to that found in the approved Product Information.

Please review the full Product Information before prescribing.

arrow

FAQs for BLINCYTO® administration Document

Download

FAQs for BLINCYTO® administration video

A PHARMACIST’S GUIDE TO BLINCYTO® ADMINISTRATION

A video developed in collaboration with Consultant Pharmacist,

Jim Siderov

Created specifically for pharmacists who prepare BLINCYTO® for infusion in their practice,

Watch

The 15-minute video features:

  • A summary of the indications and mechanism of action of BLINCYTO® [00:13]
  • An overview of the clinical evidence supporting the use of BLINCYTO® [02:14]
  • A guide on dosing and administration [08:12]
  • Step-by-step instructions on how to correctly prepare BLINCYTO® for infusion [11:06]

A PRACTICAL GUIDE TO BLINCYTO® FOR HAEMATOLOGISTS

A video developed in collaboration with Consultant Haematologist

Dr Shaun Fleming

Watch

The full video features:

  • A summary of BLINCYTO® clinical data [01:47]
  • A review of how BLINCYTO® is administered [06:40]
  • Potential adverse events and their management [11:26]
  • Case vignette [16:07]

November 2022 AU-15230

PBS Information: This product is listed on the PBS as a Section 100 item. Refer to PBS Schedule for full authority listing.

REFER TO FULL PRODUCT INFORMATION BEFORE PRESCRIBING; AVAILABLE FROM AMGEN AUSTRALIA PTY LTD,
PH: 1800 803 638 OR AT WWW.AMGEN.COM.AU/BLINCYTO.PI

For more information on BLINCYTO®, or to report an adverse event or product complaint involving BLINCYTO®, please contact Amgen Medical Information on 1800 803 638 or visit www.amgenmedinfo.com.au

WARNING: The following have occurred in patients receiving BLINCYTO®:

  • Cytokine Release Syndrome, which may be life-threatening or fatal
  • Neurological toxicities, which may be severe, life-threatening, or fatal
  • Reactivation of JC viral infection Interrupt or discontinue BLINCYTO® as recommended if any of these adverse events occur

(See Section 4.4 Special warnings and precautions for use and Section 4.2 Dose and method of administration).

This site is intended for Australian Healthcare Professionals only.